|
|
Article: Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox.
- Article from:
- PR Newswire
- Article date:
- November 6, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral agent being developed for the treatment of smallpox, as well as other serious viral infections.
Randall Lanier, Ph.D., Director of Virology for Chimerix, spoke at the WHO 11th meeting of the Advisory Committee on Variola Virus Research in Geneva, Switzerland, on ...
Related newspaper, magazine, and journal articles:
|
|
Article: Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating ...
PR Newswire;
July 16, 2009 ;
700+ words
... ... N.C., July 16 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing ... reporting to George Painter, Ph.D., Chimerix's President and Chief Executive Officer ... experience significantly strengthens the Chimerix management team," said Dr. Painter ...
|
|